Angiotensin II receptor antagonists: A new approach to blockade of the renin-angiotensin system

American Heart Journal

Volumn 127, Issue 5, 1994, Pages 1388-1401

  Kang, Peter M ^a   Landau, Andre J ^a   Eberhardt, Robert T ^a   Frishman, William H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 [N PROPYL N [2' (1H TETRAZOL 5 YL)BIPHENYL 4 YLMETHYL]AMINO]NICOTINIC ACID; 2 BUTYL 1 (4 CARBOXYBENZYL) 4 CHLORO 5 IMIDAZOLEACETIC ACID; 2 BUTYL 1 [4 (2 CARBOXYBENZAMIDO)BENZYL] 4 CHLORO 5 IMIDAZOLEACETIC ACID METHYL ESTER; 2 BUTYL 1 [4 (6 CARBOXY 2,5 DICHLOROBENZOYLAMINO)BENZYL] 6 [N (METHYLAMINOCARBONYL) N PENTYLAMINO]BENZIMIDAZOLE; 2 BUTYL 4 CHLORO 1 (2 CHLOROBENZYL) 5 IMIDAZOLEACETIC ACID; 2 BUTYL 4 CHLORO 1 (2 NITROBENZYL) 5 IMIDAZOLEACETIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; 4' (2 BUTYL 4 CHLORO 5 HYDROXYMETHYL 1H IMIDAZOL 1 YLMETHYL) 2 BIPHENYLCARBOXYLIC ACID; 4' (2 BUTYL 5 FORMYL 1H IMIDAZOL 1 YLMETHYL) 2 BIPHENYLCARBOXYLIC ACID; 4' [2 (1 BUTENYL) 4 CHLORO 5 HYDROXYMETHYL 1H IMIDAZOL 1 YLMETHYL] 2 BIPHENYLCARBOXYLIC ACID; ANGIOTENSIN II ANTAGONIST; BIBS 39; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; EXP 9654; LOSARTAN; LOSARTAN POTASSIUM; SARALASIN; SC 51316; UNCLASSIFIED DRUG; ZOLASARTAN;

CONGESTIVE HEART FAILURE; HEART HYPERTROPHY; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMAL; COMPARATIVE STUDY; DEPRESSION, CHEMICAL; HEMODYNAMICS; HUMAN; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0028263639     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/0002-8703(94)90061-2     Document Type: Article

References (155)

1. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis
2. The renin-angiotensin system
3. Renin-angiotensin system: biology, physiology and pharmacology
4. Recommendations for Routine Blood Pressure Measurement by Indirect Cuff Sphygmomanometry
5. Long-term efficacy of captopril in renovascular and essential hypertension
6. A placebo-controlled trial of captopril in refractory chronic congestive heart failure
7. Effects of Enalapril on Mortality in Severe Congestive Heart Failure
8. Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure
9. Nonpeptide angiotensin II receptor antagonists
10. Angiotensin II receptor antagonists: from discovery to antihypertensive drugs
11. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent
12. Mechanical Trauma and Acute Neuralgia Associated With Automated Ambulatory Blood Pressure Monitoring
13. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent
14. Effects of angiotensin subtype 1 and subtype 2 receptor antagonists in normotensive versus hypertensive rats
15. Competitive antagonism of pressor responses of angiotensin II and angiotensin III by the angiotensin II-1 receptor ligand losartan
16. Antihypertensive and hormonal activity of MK 954 in spontaneously hypertensive rats
17. Angiotensin II receptor antagonist losartan has persistent effects on blood pressure in the young spontaneously hypertensive rat: lack of relation to vascular structure
18. Dose-response relationships following oral administration of DuP 753 to normal humans.
19. Oral administration of DUP 753, a specific angiotensin II receptor antagonist, to normal volunteers: inhibition of pressor response to exogenous angiotensin I and II
20. Clinical experience with angiotensin II receptor antagonists.
21. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist
22. Antihypertensive effect of a non-peptide angiotensin II receptor antagonist, MK 954, in patients with essential hypertension [Abstract]
23. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension
24. The Role of Peptides in Hypertension
25. Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report.
26. Molecular Mechanisms of Renin Release
27. Large conduit arteries in hypertension: role of the vascular renin- angiotensin system
28. Tissue renin-angiotensin system in myocardial hypertrophy and failure
29. New approaches to the study of the cellular biology of the cardiovascular system
30. Angiotensin II-forming pathways in normal and failing human hearts
31. Angiotensin I and II. Some early observations made at the Cleveland Clinic Foundation and recent discoveries relative to angiotensin II formation in human heart.
32. Intracardiac generation of angiotensin and its physiologic role
33. Losartan, a specific angiotensin II receptor antagonist, increases angiotensin I and angiotensin II release from isolated rat hind legs: evidence for locally regulated renin-angiotensin system in vascular tissue
34. The angiotensin II receptor and the actions of angiotensin II
35. Solubilization and characterization of adrenal and uterine angiotensin II receptors after photoaffinity labelling
36. Identification of angiotensin II receptor subtypes
37. Angiotensin II receptor heterogeneity.
38. Angiotensin II receptor subtypes
39. Cloning and characterization of a human angiotensin II type 1 receptor
40. Cloning, characterization and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome
41. Angiotensin II receptor subtypes in cultured rat renal mesangial cells
42. Angiotensin II Receptor Subtypes
43. Pharmacology of nonpeptide angiotensin II receptor antagonists
44. Characterization of angiotensin II receptor subtypes in the rat spleen
45. Regional distribution of the two subtypes of angiotensin II receptors in rat brain using selective nonpeptide antagonists
46. Characterization of glomerular angiotensin II receptor subtypes
47. Characterization of renal angiotensin II receptors using subtype selective antagonists
48. 1 angiotensin receptors
49. A specific competitive antagonist of the vascular action of angiotensin II
50. Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats
51. Development of a high renin model of hypertension in the Cynomolgus monkey
52. Use of angiotensin II antagonist (saralasin) in the recognition of “angiotensinogenic” hypertension
53. Hypertension in man: exposure of the renin and sodium components using angiotensin II blockade
54. The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists.
55. Nonpeptide angiotensin II receptor antagonists. I. Pharmacological characterization of 2-N-Butyl-4-chloro-1-(2-chlorobenzyl)imidazole-5-acetic acid, sodium salt (S-8307)
56. Non-peptide angiotensin II receptor antagonists. II. Pharmacology of S-8308
57. pA, A NEW SCALE FOR THE MEASUREMENT OF DRUG ANTAGONISM
58. Nonpeptide angiotensin II receptor antagonist. IV. EXP6155 and EXP6803
59. Nonpeptide angiotensin II receptor antagonist: a novel class of antihypertensive agents
60. Nonpeptide angiotensin II receptor antagonists
61. Nonpeptide angiotensin II receptor antagonist: studies with EXP 9270 and DuP 753
62. DuP 753 is a specific antagonist for the angiotensin receptor
63. In vitro pharmacology of DuP 753.
64. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent
65. DuP 753 is a potent nonpeptide antagonist of angiotensin II receptors in isolated perfused rat kidney and cultured renal cells.
66. Characterization of the renal microvascular effects of angiotensin II antagonist, DuP 753: studies in isolated perfused hydronephrotic kidneys.
67. Effects of DuP 753 on proximal nephron and renal transport.
68. Effects of DuP 753 on renal function of normotensive and spontaneously hypertensive rats.
69. Effects of the nonpeptide angiotensin II receptor antagonist DuP 753 on blood pressure and renal functions in spontaneously hypertensive PH dogs.
70. Nonpeptide angiotensin II receptor antagonists: studies with DuP 753 and EXP3174 in dogs
71. Nonpeptide angiotensin II receptor antagonist. XI. Pharmacology of EXP 3174: an active metabolite of DuP 753, an orally active antihypertensive agent
72. Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs
73. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566
74. Characterization of BIBS 39 and BIBS 222: two new nonpeptide angiotensin II receptor antagonists
75. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonists
76. In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist
77. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist
78. Characterization of the binding of [3H]L-158,809: a new potent and selective nonpeptide angiotensin II receptor (AT1) antagonist radioligand
79. In vitro pharmacology of a nonpeptide angiotensin II receptor antagonist, SC-51316
80. Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats
81. Discovery of a novel class of orally active, non-peptide angiotensin II antagonists
82. 109. Efficacy and safety of oral MK-954 (DuP 753), an angiotensin receptor antagonist, in essential hypertension
83. Angiotensin II receptor blockade. An innovative approach to cardiovascular pharmacotherapy
84. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors
85. Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors
86. Captopril-associated neutropenia. Who is at risk?
87. Enalapril worldwide experience
88. Angiotensin-converting enzyme and the cough reflex
89. Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough: a research review
90. Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions
91. Captopril and renal autoregulation
92. Captopril-induced functional renal insufficiency in patients with bilateral renal artery stenosis or a solitary kidney
93. Kinin contribution to renal vasodilator effect of captopril in rabbit
94. Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats: nonpeptide angiotensin II receptor antagonist
95. Comparison of systemic and regional hemodynamic effects of a diuretic, an angiotensin II receptor antagonist, and an angiotensin-converting enzyme inhibitor in conscious renovascular hypertensive rats
96. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells.
97. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells
98. Long-term angiotensin II antagonism in spontaneously hypertensive rats: effects of blood pressure and cardiovascular amplifiers
99. Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats
100. Angiotensin II-1 receptors mediate both vasoconstrictor and hypertrophic responses in rat aortic smooth muscle cells
101. Chronic captopril and losartan (DuP 753) administration in rats with high-output heart failure
102. 1 receptor
103. Cardiac angiotensin receptors: effects of selective angiotensin II receptor antagonists, DuP 753 and PD 121981, in rabbit heart
104. High renin/sodium phenotype predicts myocardial infarction: renin hypothesis confirmed [Abstract]
105. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor
106. Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts
107. Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart
108. Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure.
109. Angiotensin II receptor antagonism in bovine heart failure: acute hemodynamic, hormonal, and renal effects
110. Autocrine angiotensin system regulation of bovine aortic endothelial cell migration and plasminogen activator involves modulation of proto-oncogene pp60 (c-src) expression
111. Significance of quiescent smooth muscle migration into the injured rat carotid artery
112. Balloon angioplasty enhanced the expression of angiotensin II AT1 receptors in neointima of rat aorta
113. Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, losartan
114. Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries
115. Replication of smooth muscle cells in vascular disease
116. Phenotypic features of smooth muscle cells during the evolution of experimental carotid artery intimal thickening: biochemical and morphological studies
117. Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells form spontaneously hypertensive rats
118. Relation between Activated Smooth-Muscle Cells in Coronary-Artery Lesions and Restenosis after Atherectomy
119. Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist: effects on smooth muscle cell migration and proliferation after balloon catheter injury
120. Role of angiotensin II in injury-induced neointima formation in rats
121. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group
122. Renal Effects of Converting Enzyme Inhibition
123. Enalapril improved renal function and proteinuria in chronic glomerulopathies
124. Long-term stabilizing effects of angiotensin-converting enzyme inhibition on plasma creatine and on proteinuria in normotensive type II diabetic patients
125. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy
126. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.
127. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension
128. A comparison of the characteristics of angiotensin receptors in the renal and mesenteric vascular beds of the anesthetized cat
129. Renal-specific actions of angiotensin II receptor antagonism in the anesthetized dog
130. 2 subtype-specific angiotensin II ligands
131. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass
132. Effect of captopril and the nonpeptide angiotensin II antagonists, SK&F 108566 and EXP3174, on renal function on dogs with a renal artery stenosis
133. Role of angiotensin in autoregulation of cerebral blood flow
134. DuP 753 increases survival in spontaneously hypertensive stroke-prone rats fed a high sodium diet.
135. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease
136. Angiotensin II receptor antagonist markedly reduces mortality in salt-loaded Dahl S rats.
137. Central administration of angiotensin II receptor antagonists and arterial pressure regulation: a note of caution
138. Depressor effect of blocking angiotensin subtype 1 receptors in anterior hypothalamus
139. The role of angiotensin, AT1 and AT2 receptors in the pressor, drinking and vasopression responses to central angiotensin
140. Effects of a nonpeptide angiotensin receptor antagonist on drinking and blood pressure responses to centrally administered angiotensin in the rat
141. 2 receptor antagonist WL 19
142. 2 antagonist, CGP 42112B
143. Effect of a nonpeptide angiotensin II receptor antagonist, DuP 753, on angiotensin-related water intake in rats
144. Central and peripheral actions of a nonpeptide angiotensin II receptor antagonist
145. Losartan potassium, a nonpeptide antagonist of angiotensin II, chronically administered p.o. doses not readily cross the blood-brain barrier
146. Central DuP753 does not lower blood pressure in spontaneously hypertensive rats
147. Effect of blocking angiotensin II receptor subtype on rat sympathetic nerve function
148. Effect of angiotensin II antagonism on canine renal sympathetic nerve function
149. Functions of angiotensin in the central nervous system
150. Non-peptide angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor: effect on a renin-induced deficit of a passive avoidance response in rats
151. The mas oncogene encodes an angiotensin receptor
152. 1 receptor antagonist, and surgical reversal
153. Effects of an angiotensin II receptor antagonist, CV-11974, on angiotensin II-induced increases in cytosolic free calcium concentration, hyperplasia, and hypertrophy of cultured vascular smooth muscle cells